Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma 17Leukemia, Myeloid, Acute 16Breast Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 11Carcinoma, Non-Small-Cell Lung 11Lymphoma, Mantle-Cell 10Leukemia 10Lymphoma, Follicular 9Hodgkin Disease 9Myelodysplastic Syndromes 8Recurrence 7Neuroblastoma 7Neoplasm Metastasis 7Leukemia, Lymphocytic, Chronic, B-Cell 7Brain Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, B-Cell, Marginal Zone 6Lung Neoplasms 6Glioblastoma 6Prostatic Neoplasms 5Pancreatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, B-Cell 5Immunoblastic Lymphadenopathy 5Burkitt Lymphoma 5

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Melanoma × Vorinostat × Clear all
NCT02836548 2025-07-10

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

The Netherlands Cancer Institute

Phase 1/2 Completed
33 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡